Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOTS vs Enhanced DOTS for TB Control
NCT00317330Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifapentine in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2004; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00317330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317330.